Linked Life Data

18793670

Source:http://linkedlifedata.com/resource/pubmed/id/18793670

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-10-20
pubmed:abstractText
L-carnitine (LC) deficiency is commonly observed in chronic hemodialysis (HD) patients. As a result of this and other causes of secondary LC deficiencies, LC has been described as a "conditionally essential nutrient" or "conditional vitamin". Although a large number of clinical trials regarding the beneficial effects of LC administration in HD patients have been published, some controversy about its use in this indication persists. In this article, we will review the use of LC in dialysis patients, by focussing mainly on those experimental and clinical data supporting the notion that supra-physiological concentrations of LC in plasma and target organs may exert beneficial effects on several metabolic parameters that have derangements of a common origin (e.g. insulin resistance, type 2 diabetes, dyslipidemia) and which are frequently present in end-stage renal disease (ESRD) patients undergoing dialysis.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0163-7258
pubmed:author
pubmed:issnType
Print
pubmed:volume
120
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
149-56
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Carnitine in metabolic disease: potential for pharmacological intervention.
pubmed:affiliation
R&D Department, Iperboreal Pharma Srl, Chieti, Italy. a.arduini@iperboreal-pharma.com
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't